Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a cytotoxic anti-cancer drug directly to the tumor site with reduced off-target damage. ADCs combine the targeting capability of monoclonal antibodies with the cancer-killing capability of the payload (linker + cytotoxic drug). Virtual pharmacokinetic studies using the Simcyp Simulator physiologically-based pharmacokinetic (PBPK) modeling platform can inform first-in-human dose selection, concentration at the target site, and predict drug-drug interactions (DDIs) between the small molecule payload and other co-medications. Furthermore, the disposition of ADCs can be modeled in special populations for whom conducting clinical studies is challenging. This webinar will present the modeling capabilities of the Simcyp Biologics Simulator for ADCs and show how it can help drug development programs save time and money.Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a cytotoxic anti-cancer drug directly to the tumor site with reduced off-target damage. ADCs combine the targeting capability of monoclonal antibodies with the cancer-killing capability of the payload (linker + cytotoxic drug). Virtual pharmacokinetic studies using the Simcyp Simulator physiologically-based pharmacokinetic (PBPK) modeling platform can inform first-in-human dose selection, concentration at the target site, and predict drug-drug interactions (DDIs) between the small molecule payload and other co-medications. Furthermore, the disposition of ADCs can be modeled in special populations for whom conducting clinical studies is challenging. This webinar presented the modeling capabilities of the Simcyp Biologics Simulator for ADCs and showed how it can help drug development programs save time and money.